Genentech to present obesity drug trial data at ADA meeting

Genentech will present Phase II data on two obesity candidates, enicepatide and petrelintide, at ADA Scientific Sessions on June 5-8, with a virtual investor event set for June 8. The company said both programs are moving toward Phase III, and it plans a mid-2026 Phase II combination trial. The article is mostly a pipeline update, offset by mixed analyst actions on Roche, including Morgan Stanley's $46 target cut on FX headwinds and Argus's Buy upgrade with a $55 target.

Analysis

CME’s move to 24/7 crypto futures is more important for market structure than for near-term flow. It reduces the weekend gap premium embedded in spot crypto and should tighten the basis as institutional hedgers can now rebalance continuously; the first-order winner is CME’s own derivatives franchise, but the second-order effect is a slow migration of price discovery away from fragmented offshore venues toward regulated rails. That tends to compress volatility over time, even if it initially boosts turnover as systematic funds and market makers recalibrate around a new trading regime.

For Roche, the obesity program is a portfolio-option story rather than a near-term earnings story. The market is likely underestimating how much value comes from having both a dual-agonist and an amylin asset: combination optionality is what matters if efficacy/tolerability tradeoffs force the field toward multi-mechanism regimens, which would favor companies with internal assets over single-product players. The key second-order risk is capital allocation; moving both assets into Phase III while funding combo trials raises the bar for clinical differentiation and could pressure operating margins if the program scales faster than investor confidence in eventual share capture.

Morgan Stanley’s FX call on Roche is a reminder that for large European healthcare names, reported-growth optics can swamp fundamentals over 1-2 quarters. If the currency headwind persists, investors may discount even good clinical news because they anchor on translation drag and the absence of an immediate revenue inflection. That creates a setup where positive obesity data may need to be significantly better than consensus to re-rate the stock, while a clean upside surprise on margins or guidance would have asymmetric impact.

The contrarian read is that the obesity opportunity may be overcrowded at the headline level but still under-owned in the less obvious names. If combination therapy becomes the market’s preferred endpoint, platform owners with peptide-formulation and combo know-how should be valued more like tool-and-platform businesses than single-asset pharma. Meanwhile, CME’s structural upgrade is a quieter but cleaner monetization event than directional crypto exposure: it should benefit from higher institutional participation regardless of whether bitcoin rallies or merely becomes more tradable.

Key Decisions for Investors

• Long CME vs. short a basket of crypto beta proxies for 3-6 months: structural market-share gain should matter more than spot direction; target is higher futures volume and stickier fee capture with limited dependence on BTC price appreciation.
• Buy CME call spreads into the first 4-8 weeks of the 24/7 rollout: use a defined-risk structure to capture a likely step-up in activity and volatility premium while capping downside if volumes disappoint.
• For Roche (ROP), prefer a tactical long only on data-day weakness, not pre-event momentum; the setup is better as a 1-3 month trade because the re-rate likely depends on combo-trial credibility, not just single-study readouts.
• Express the obesity platform thesis via a pair: long ROP / short a lower-quality single-asset obesity beneficiary with stretched expectations over 3-6 months; the winner should be the company with follow-on optionality if the field moves to combination regimens.
• If you want a lower-risk hedge, avoid adding MS here: the FX headwind thesis makes it a less attractive long into the next quarter unless you are specifically trading the setup on a pullback after consensus resets.